Promoting Optimal Treatment for Community-acquired Pneumonia in the Emergency Room (PIONEER)

NACompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

March 30, 2024

Study Completion Date

April 18, 2024

Conditions
Community-acquired Pneumonia
Interventions
OTHER

Novel Care Pathway

The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.

Trial Locations (1)

L8S 4K1

McMaster Children's Hospital, Hamilton

All Listed Sponsors
lead

Hamilton Health Sciences Corporation

OTHER